About us Contacts Drug interactions: 390 212
Drug search by name

Mometasone Inhalation Powder and PCE Dispertab

Determining the interaction of Mometasone Inhalation Powder and PCE Dispertab and the possibility of their joint administration.

Check result:
Mometasone Inhalation Powder <> PCE Dispertab
Relevance: 16.12.2022 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Erythromycin may increase the absorption of mometasone into the blood stream. In some cases, this can increase side effects such as swelling, weight gain, high blood pressure, high blood glucose, muscle weakness, depression, acne, thinning skin, stretch marks, easy bruising, bone density loss, cataracts, menstrual irregularities, excessive growth of facial or body hair, and abnormal distribution of body fat, especially in the face, neck, back, and waist. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. Other side effects that may occur include decreased ability to fight infections, increased risk of developing infections, and inadequate response to stress such as infection, surgery, trauma, or a severe asthma attack. Children may experience a reduced growth rate due to excessive effects of mometasone. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Professional:

MONITOR: Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of mometasone, which is primarily metabolized by the isoenzyme. In healthy subjects coadministered mometasone (400 mcg inhaled twice daily for 9 days) with the potent CYP450 3A4 inhibitor ketoconazole (200 mg orally twice daily on days 4 to 9), 4 out of 12 subjects had peak plasma concentrations of mometasone increase from less than 150 pcg/mL on day 3 before the addition of ketoconazole to more than 200 pcg/mL afterwards. Serum cortisol AUC also decreased slightly after ketoconazole was added. The clinical significance of these findings is unknown.

MANAGEMENT: The possibility of increased systemic adverse effects of mometasone should be considered during coadministration with potent CYP450 3A4 inhibitors. Some authorities advise against concomitant use unless the potential benefit outweighs the risk. If the combination cannot be avoided, the dosing times between mometasone and the CYP450 3A4 inhibitor should be separated by as much as possible. In addition, the lowest effective dosage of mometasone should be prescribed, and further adjustments made as necessary according to therapeutic response and tolerance. Alternatively, a less potent, less lipophilic, and/or shorter-acting agent such as beclomethasone may be considered. Beclomethasone is also less dependent on CYP450 3A4 metabolism. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents.

References
  • "Product Information. Dulera (formoterol-mometasone)." Schering-Plough Corporation, Kenilworth, NJ.
  • "Multum Information Services, Inc. Expert Review Panel"
  • EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."
  • "Product Information. Nasonex nasal spray (mometasone topical)." Schering Laboratories, Kenilworth, NJ.
  • "Product Information. Asmanex Twisthaler (mometasone)." Schering-Plough Corporation, Kenilworth, NJ.
  • Agencia EspaƱola de Medicamentos y Productos Sanitarios Healthcare "Centro de informaciĆ³n online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):
  • Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Mometasone Inhalation Powder

Generic Name: mometasone

Brand name: Asmanex HFA, Asmanex Twisthaler 120 Dose, Asmanex Twisthaler 14 Dose, Asmanex Twisthaler 30 Dose, Asmanex Twisthaler 60 Dose, Asmanex Twisthaler 7 Dose, Asmanex Twisthaler

Synonyms: Mometasone inhalation, Mometasone (Oral Inhalation)

PCE Dispertab

Generic Name: erythromycin

Brand name: EES. Granules, EES-400 Filmtab, EryPed 200, EryPed 400, Ery-Tab, Erythrocin Lactobionate, Erythrocin Stearate Filmtab, PCE Dispertab, E. E. S, EryPed, Erythrocin, Erythromycin Filmtabs, Erythromycin Lactobionate - IV

Synonyms: PCE Dispertab (Oral), PCE, PCE (Oral)

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

Interaction with food and lifestyle